GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general med...
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 95
- Registration Number
- NCT06521567
- Locations
- 🇺🇸
GSK Investigational Site, Iowa City, Iowa, United States
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT06517875
Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT06506266
- Locations
- 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT06497504
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications
Not yet recruiting
- Conditions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 52000
- Registration Number
- NCT06488703
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1000
- Registration Number
- NCT06472076
- Locations
- 🇹🇷
GSK Investigational Site, Izmir, Turkey
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 159
- Registration Number
- NCT06447506
- Locations
- 🇹🇭
GSK Investigational Site, Pathumthani, Thailand
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 91
- Registration Number
- NCT06433921
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT06433908
- Locations
- 🇳🇱
GSK Investigational Site, Groningen, Netherlands
A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
Phase 2
Recruiting
- Conditions
- Interventions
- Biological: Flu Seasonal mRNA Formulation 1Biological: Flu Seasonal mRNA Formulation 2Biological: Flu Seasonal mRNA Formulation 3Biological: Flu Seasonal mRNA Formulation 4Combination Product: Active Comparator 1Biological: Flu Seasonal mRNA Formulation 5Biological: Flu Seasonal mRNA Formulation 6Biological: Flu Seasonal mRNA Formulation 7Biological: Flu Seasonal mRNA Formulation 8Combination Product: Active Comparator 2Biological: Flu Seasonal mRNA Formulation 9Combination Product: Active Comparator 3Biological: Flu Seasonal mRNA Formulation 10Combination Product: Active Comparator 4
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 838
- Registration Number
- NCT06431607
- Locations
- 🇺🇸
GSK Investigational Site, Norfolk, Virginia, United States
© Copyright 2024. All Rights Reserved by MedPath